Literature DB >> 25108024

Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling.

Joonbeom Bae1, Suk Jun Lee2, Chung-Gyu Park3, Young Sik Lee1, Taehoon Chun4.   

Abstract

Lymphocyte activation gene-3 (LAG-3; CD223), a structural homolog of CD4, binds to MHC class II molecules. Recent research indicated that signaling mediated by LAG-3 inhibits T cell proliferation, and LAG-3 serves as a key surface molecule for the function of regulatory T cells. Previous reports demonstrated that the majority of LAG-3 is retained in the intracellular compartments and is rapidly translocated to the cell surface upon stimulation. However, the mechanism by which LAG-3 translocates to the cell surface was unclear. In this study, we examined the trafficking of human LAG-3 under unstimulated as well as stimulated conditions of T cells. Under the unstimulated condition, the majority of LAG-3 did not reach the cell surface, but rather degraded within the lysosomal compartments. After stimulation, the majority of LAG-3 translocated to the cell surface without degradation in the lysosomal compartments. Results indicated that the cytoplasmic domain without Glu-Pro repetitive sequence is critical for the translocation of LAG-3 from lysosomal compartments to the cell surface. Moreover, protein kinase C signaling leads to the translocation of LAG-3 to the cell surface. However, two potential serine phosphorylation sites from the LAG-3 cytoplasmic domain are not involved in the translocation of LAG-3. These results clearly indicate that LAG-3 trafficking from lysosomal compartments to the cell surface is dependent on the cytoplasmic domain through protein kinase C signaling in activated T cells.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25108024     DOI: 10.4049/jimmunol.1401025

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation.

Authors:  Takeo K Maeda; Daisuke Sugiura; Il-Mi Okazaki; Takumi Maruhashi; Taku Okazaki
Journal:  J Biol Chem       Date:  2019-02-13       Impact factor: 5.157

Review 2.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

Authors:  Elisa Ruffo; Richard C Wu; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

Review 3.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

4.  Fewer LAG-3+ T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes.

Authors:  Britta E Jones; Megan D Maerz; Henry T Bahnson; Ashwin Somasundaram; Lucas H McCarthy; Cate Speake; Jane H Buckner
Journal:  J Immunol       Date:  2022-01-12       Impact factor: 5.422

5.  Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.

Authors:  Anne Fröhlich; Judith Sirokay; Simon Fietz; Timo J Vogt; Jörn Dietrich; Romina Zarbl; Mike Florin; Pia Kuster; Gonzalo Saavedra; Susana Ramírez Valladolid; Friederike Hoffmann; Lukas Flatz; Sandra S Ring; Carsten Golletz; Torsten Pietsch; Sebastian Strieth; Peter Brossart; Gerrit H Gielen; Glen Kristiansen; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  EBioMedicine       Date:  2020-08-30       Impact factor: 8.143

6.  The Future Liver Remnant in Patients Undergoing the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy (ALPPS) Maintains the Immunological Components of a Healthy Organ.

Authors:  Ram Venkatesh Anantha; Christopher Ryan Shaler; Courtney Erin Meilleur; Jeremy Parfitt; S M Mansour Haeryfar; Roberto Hernandez-Alejandro
Journal:  Front Med (Lausanne)       Date:  2016-08-04

7.  LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.

Authors:  Ruea-Yea Huang; Cheryl Eppolito; Shashikant Lele; Protul Shrikant; Junko Matsuzaki; Kunle Odunsi
Journal:  Oncotarget       Date:  2015-09-29

Review 8.  Understanding LAG-3 Signaling.

Authors:  Luisa Chocarro; Ester Blanco; Miren Zuazo; Hugo Arasanz; Ana Bocanegra; Leticia Fernández-Rubio; Pilar Morente; Gonzalo Fernández-Hinojal; Miriam Echaide; Maider Garnica; Pablo Ramos; Ruth Vera; Grazyna Kochan; David Escors
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

Review 9.  Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators.

Authors:  Isabelle Le Mercier; J Louise Lines; Randolph J Noelle
Journal:  Front Immunol       Date:  2015-08-21       Impact factor: 7.561

10.  Tr1-Like T Cells - An Enigmatic Regulatory T Cell Lineage.

Authors:  Anna Malgorzata White; David C Wraith
Journal:  Front Immunol       Date:  2016-09-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.